跳至主要内容
临床试验/CTRI/2023/01/049011
CTRI/2023/01/049011招募中未知

Intravenous Magnesium Sulphate as a second line therapy in children between 2 to 16 years admitted to PICU with acute severe asthma- A Randomised control trial. - none

Surya Mother and Child Superspeciality hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • All children between 2- 16 years of age with moderate to severe acute asthma defined as PRAM (Pediatric respiratory assessment measure) score > 5 inspite of first line therapy with short acting beta agonists and corticosteroids.

排除标准

  • 1.First episode of wheezing or alternative diagnosis like foreign body aspiration.
  • 2.Coexisting pneumonia defined as radiological abnormalities like infiltrates or opacities on chest Roentgenogram.
  • 3.Patients needing ventilator support.
  • 4.Patients who have underlying cardiac, renal, neurologic or pulmonary dysfunction contraindicating the use of magnesium sulphate or aminophylline
  • 5.Known hypersensitivity to Magnesium sulphate or aminophylline.

研究者

发起方
Surya Mother and Child Superspeciality hospital

相似试验